NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)

CompletedNA

Sponsor: Assaf-Harofeh Medical Center

Conditions: COVID-19, Desaturation of Blood

Interventions: Hyperbaric oxygen therapy

Countries: Israel

The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic.So far, no specific treatment has proven efficacy. Recent case series reported the use of Hyperbaric Oxygen Therapy (HBOT) on 5 severe COVID-19 patients who developed respiratory insufficiency. HBOT mechanisms of tissue oxygenation and anti-inflammatory effect may explain these findings. The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Within 7 days of patient's need of oxygen supply
* Positive SARS-CoV-2 RT-PCR
* At least one risk factor for bad prognosis of COVID-19: Moderate-severe Asthma, Diabetes mellitus, Cardiac conditions (congestive heart failure, coronary disease, cardiomyopathy, pulmonary hypertension), severe obesity (BMI\>40), age\>65, immunodeficiency, chronic liver disease.
* Respiratory insufficiency : Room Air SpO2 \<94% or PaO2/FiO2\<300mmHg
* Age\>18
* Ability to sign an informed consent

Exclusion Criteria:

* HBOT contraindication: pneumothorax, pneumomediastinum, claustrophobia, ear/sinus disease which aren't allowed in HBOT, known chronic pulmonary disease: severe emphysema or known pulmonary bullae.
* Pregnancy
* Inability to sign an informed consent

Locations (1)

Ẕerifin, Israel